Abstract
Hypertension is often difficult to control in patients with chronic kidney disease. Clinicians often view thiazide and thiazide-like diuretics as being ineffective in reducing blood pressure in patients with chronic kidney disease, and prefer to use loop diuretics, especially if the estimated glomerular filtration rate (eGFR) is below 50 ml/min/1.73m2. Recent clinical trial data indicate that thiazide and thiazide-like diuretics possess important and clinically significant antihypertension properties, that are likely independent of volume reduction, even in patients with eGFR in the 15-45 ml/min range. Thiazide and thiazide-like diuretics should be given consideration for use in the treatment of hypertension in patients with chronic kidney disease, especially if there is no clinical evidence of volume overload.
Keywords: Antihypertensive drug therapy, Blood pressure, Chronic kidney disease, CKD, GFR, Glomerular filtration rate, Hypertension, Loop diuretics, Thiazide, Thiazide-like diuretics.
Current Hypertension Reviews
Title:The Use of Thiazides in Chronic Kidney Disease
Volume: 10 Issue: 2
Author(s): Feras Karadsheh and Matthew R. Weir
Affiliation:
Keywords: Antihypertensive drug therapy, Blood pressure, Chronic kidney disease, CKD, GFR, Glomerular filtration rate, Hypertension, Loop diuretics, Thiazide, Thiazide-like diuretics.
Abstract: Hypertension is often difficult to control in patients with chronic kidney disease. Clinicians often view thiazide and thiazide-like diuretics as being ineffective in reducing blood pressure in patients with chronic kidney disease, and prefer to use loop diuretics, especially if the estimated glomerular filtration rate (eGFR) is below 50 ml/min/1.73m2. Recent clinical trial data indicate that thiazide and thiazide-like diuretics possess important and clinically significant antihypertension properties, that are likely independent of volume reduction, even in patients with eGFR in the 15-45 ml/min range. Thiazide and thiazide-like diuretics should be given consideration for use in the treatment of hypertension in patients with chronic kidney disease, especially if there is no clinical evidence of volume overload.
Export Options
About this article
Cite this article as:
Karadsheh Feras and Weir R. Matthew, The Use of Thiazides in Chronic Kidney Disease, Current Hypertension Reviews 2014; 10 (2) . https://dx.doi.org/10.2174/1573402111666141231150213
DOI https://dx.doi.org/10.2174/1573402111666141231150213 |
Print ISSN 1573-4021 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6506 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chronic Deposition of Aβ Influences Microcirculation in the Chronic Stage of Cerebral Ischemia
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Amniotic Fluid Embolism: Moving Diagnosis Through the Time. From the Mechanical Pulmonary Vascular Occlusion Until An Immuno - Inflammatory Pathogenesis?
Current Pharmaceutical Biotechnology Renal Effects of Non-Steroidal Anti-Inflammatory Drugs and Selective Cyclooxygenase-2 Inhibitors
Current Pharmaceutical Design A Viewpoint on Potential Biomarkers for Infectious COVID-19 Severity: An Updated Literature Survey
Infectious Disorders - Drug Targets Perception of Symptoms in Hypertensive Patients and the Relevance to the Application of Anti- Hypertensive Drug Therapy
Current Pharmaceutical Design Arterial Stiffness:A Potential Therapeutic Target to Reduce Cardiovascular Mortality
Current Hypertension Reviews Heteromerization as a Mechanism Modulating the Affinity of the ACE2 Receptor to the Receptor Binding Domain of SARS-CoV-2 Spike Protein
Current Proteomics Endogenous Cardioprotective Agents: Role in Pre and Postconditioning
Current Drug Targets Primary Antiphospholipid Syndrome and Pulmonary Hypertension
Current Pharmaceutical Design MicroRNAs: Novel Diagnostic and Prognostic Biomarkers in Atherosclerosis
Current Topics in Medicinal Chemistry Coronary Artery Disease and End-Stage Renal Disease - A Clinical Perspective
Current Hypertension Reviews Cerebroprotective Functions of HO-2
Current Pharmaceutical Design The Protective Effects of Extra Virgin Olive Oil on Immune-mediated Inflammatory Responses
Endocrine, Metabolic & Immune Disorders - Drug Targets Synthesis, Cytotoxicity and Molecular Docking Simulation of Novel bis-1,4-Dihydropyridines Linked to Aliphatic or Arene Core via Amide or Ester-Amide Linkages
Mini-Reviews in Medicinal Chemistry Aldosterone and Mineralocorticoid Receptor Antagonists on Pulmonary Hypertension and Right Ventricular Failure: A Review
Current Pharmaceutical Design Future Targets in Endothelial Biology: Endothelial Cell to Mesenchymal Transition
Current Drug Targets Recent Advances in Identification and Characterization of β-Adrenoceptor Agonists and Antagonists
Current Topics in Medicinal Chemistry Biochemical Markers of Renal Function
Current Medicinal Chemistry Prognostic Implications of Genetics in Cardiovascular Disease
Current Pharmacogenomics Age-Related Changes and Effects of Mild Hypothermia on Carotid Artery Reactivity in Newborn Rats
CNS & Neurological Disorders - Drug Targets